NCT03915223 (ICOMI) is a NA clinical trial of leg fracture in Leg Injuries, sponsored by University Hospital, Clermont-Ferrand.

Who is sponsoring NCT03915223?

NCT03915223 is sponsored by University Hospital, Clermont-Ferrand.

What drugs are being tested in NCT03915223?

Interventions in NCT03915223: leg fracture.

What condition does NCT03915223 study?

NCT03915223 studies Leg Injuries, Fracture, Edema.

Is NCT03915223 still recruiting?

NCT03915223 is currently completed. Last updated 8 May 2024.

Last reviewed 2024-05-08 · How we verify

NCT03915223: ICOMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Soft Part Management for Surgical Fractures of the Lower Limb

Completed NA Last updated 8 May 2024

What this trial tests

NA trial testing leg fracture in Leg Injuries in 104 participants. Completed in 6 May 2024.

Timeline

10 May 2019

Primary endpoint
25 December 2023

6 May 2024

Quick facts

Lead sponsor	University Hospital, Clermont-Ferrand
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	104
Start date	10 May 2019
Primary completion	25 December 2023
Estimated completion	6 May 2024
Sites	1 location across France

Drugs / interventions tested

leg fracture

Conditions studied

Leg Injuries — all drugs for Leg Injuries →
Fracture — all drugs for Fracture →
Edema — all drugs for Edema →

Sponsor

University Hospital, Clermont-Ferrand

Who can join

18 and older, any sex, with Leg Injuries or Fracture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The assessment consists in comparing corticoids injection versus placebo in surgery of lower limb fractures The aim of study is to assess (state cutaneous, efficacy, safety) corticoids injection on a prospective, randomized analysis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03915223 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
Last refreshed: 8 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03915223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing